Competition record
Sandoz
Deep profile · 1 linked library matter
Sandoz sells generic drugs and is named in a Connecticut case about dermatology products. On 11 September 2026 the court kept some drug claims against a former Perrigo executive and dropped others, and the case continues on the surviving drugs.
Overview
Sandoz manufactures generic medicines that compete with brands and with other generics after patents fall. The Connecticut case is about a set of dermatology drugs, not about every product the company sells.
On 11 September 2026 the court kept some drug claims against a former Perrigo executive and dropped others. The case continues on the drugs that survived.
Narrowing the docket is not an acquittal of the whole case. No judgment has closed the claims that remain.
Competition footprint
Generic dermatology drugs become substitutable once several manufacturers are approved, which is the market this Connecticut case is about.
The 11 September 2026 order split the claims against the former Perrigo executive by drug, keeping some and dismissing others.
Sandoz stays a named company in a docket that is smaller than it was and not finished.
Consumer & business angle
Pharmacies and patients pay for the generic cream or tube, and they are not the executive whose claims were split.
Perrigo is the company the former executive came from, and that job history is not a finding about Sandoz's prices.
What to watch
- Which dermatology drugs remain after the 11 September 2026 order.
- Whether the surviving claims against the former executive reach trial.
Markets
generic drugs · dermatology generics · generic dermatology drugs
Also known as: sandoz